Get the Stockscreener App
9.80
0.36%
-0.02
Kazia Therapeutics Limited Adr stock is traded at $9.80, with a volume of 65,641.
It is down -0.36% in the last 24 hours and down -29.33% over the past month.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
See More
Previous Close:
$9.78
Open:
$9.77
24h Volume:
65,641
Relative Volume:
0.26
Market Cap:
$153.00M
Revenue:
$26,600
Net Income/Loss:
$-14.73M
P/E Ratio:
-1.4367
EPS:
-6.8211
Net Cash Flow:
$-8.76M
1W Performance:
-6.21%
1M Performance:
-29.33%
6M Performance:
+33.49%
1Y Performance:
+32.95%
1-Day Range:
$9.595
$9.9899
1-Week Range:
$9.01
$11.25
52-Week Range:
$4.86
$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Name
Kazia Therapeutics Limited Adr
Sector
Industry
Phone
01161298780088
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
9.84 | 152.07M | 26,600 | -14.73M | -8.76M | -6.8211 |
VRTX
Vertex Pharmaceuticals Inc
|
521.21 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.62 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
193.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.55 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.39 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Laidlaw | Buy |
| Feb-06-25 | Initiated | Maxim Group | Buy |
| Oct-14-21 | Initiated | Maxim Group | Buy |
| Jan-05-21 | Initiated | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Stock (KZIA) Latest News
Kazia Therapeutics Limited (KZIA) stock price, news, quote and history - Yahoo Finance Australia
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders - Macau Business
New rare-epilepsy trial unlocks milestone cash for Kazia (NASDAQ: KZIA) - Stock Titan
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) shifts ADSs to JPMorgan - Stock Titan
Kazia Therapeutics Limited Announces Change of Sole Depositary for Its American Depositary Receipt - marketscreener.com
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Kazia Therapeutics LimitedADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Kazia Therapeutics (NASDAQ: KZIA) Shows 52% Tumor Reduction in Preclinical Colorectal Cancer Model - Kalkine Media
Paxalisib shrinks tumors in models as Kazia (NASDAQ: KZIA) lines up Phase 2 cancer trials - Stock Titan
BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Kazia Therapeutics Expands Trial in HR+/HER2- Cancer | KZIA Stock News - Stock Titan
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - The Manila Times
Kazia Therapeutics (NASDAQ: KZIA) unveils new investor site - Stock Titan
Kazia Therapeutics stock falls on $40M public offering By Investing.com - Investing.com UK
Kazia Therapeutics prices $40 million public offering By Investing.com - Investing.com UK
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering - The Globe and Mail
Kazia Therapeutics Limited Announces Proposed Public Offering - The Manila Times
Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake - Stock Titan
Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap - Stock Titan
Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS - Stock Titan
Kazia Therapeutics (KZIA) Holds Near $13.95 as Biotech ADR Consolidates Between Key LevelsParabolic SAR - vinanet.vn
Kazia files patent for breast cancer treatment strategy By Investing.com - Investing.com Nigeria
Kazia Therapeutics (NASDAQ: KZIA) files patent backed by TNBC data - Stock Titan
KZIA|Kazia Therapeutics Ltd|Price:12.802|Chg%:+0.542 - TradingKey
Kazia Therapeutics (KZIA) grants director 100,000 stock options - Stock Titan
KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant - Stock Titan
Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance - Stock Titan
Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options - Stock Titan
Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director - Stock Titan
Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78 - Stock Titan
BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria
BTIG initiates Kazia Therapeutics stock with buy on cancer drug - Investing.com
Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView
Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan
ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks - TradingView
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum AcceleratesHot Stock Picks - DonanımHaber
KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan
KZIAKazia Therapeutics Limited ADR Options - Finviz
Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan
Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan
Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.21%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):